Creatine acts as a cellular battery in immune cells fighting cancer
From a laboratory at UCLA, a familiar supplement has revealed an unexpected role in the ancient struggle between the body and cancer. Researchers led by professor Lili Yang have found that creatine — long associated with athletic performance — appears to fortify the immune system's sentinel cells, helping them sustain their vigilance even within the nutrient-starved terrain that tumors create. The discovery does not promise a cure, but it quietly expands the horizon of what immunotherapy might one day achieve for the many patients it currently cannot reach.
- Current cancer immunotherapies fail between 60 and 80 percent of patients, leaving an urgent gap that researchers are racing to close.
- Tumors actively starve immune cells of energy, creating hostile microenvironments that blunt the body's own defenses — a battlefield tilted against the immune system.
- UCLA scientists found that creatine acts as a cellular battery for dendritic cells, keeping these critical immune scouts energized and functional even under nutrient-depleted conditions.
- Animal trials showed measurably slower tumor growth in mice given daily creatine doses, with denser clusters of active immune cells forming around the tumors themselves.
- Human cell studies echoed those results, but researchers are urging caution — clinical trials are still required before any cancer patient should consider creatine a treatment tool.
Scientists at UCLA have uncovered a surprising new role for creatine, the supplement long favored by athletes: it appears to strengthen the immune cells that detect and fight cancer. The research, led by professor Lili Yang and published in iScience, focuses on dendritic cells — the immune system's scouts, responsible for identifying tumor fragments and signaling T lymphocytes to attack.
The key insight is metabolic. Tumors create environments where nutrients are scarce and immune cells struggle to sustain themselves. Creatine functions as a kind of cellular battery, storing and releasing energy as ATP precisely when immune cells need it most, allowing dendritic cells to remain active and effective even in these depleted conditions.
The experimental results were encouraging. Mice receiving daily creatine doses showed significantly slower tumor growth than control animals, with more active immune cells gathering around the tumors. Laboratory tests using human cells produced similarly promising findings, with creatine visibly improving dendritic cell activation.
The broader significance lies in immunotherapy's current limitations. Treatments designed to unleash the immune system against cancer work for only a fraction of patients. Strengthening the cells that coordinate that immune response could expand who benefits — and incorporating creatine into therapeutic cancer vaccines represents yet another possibility worth pursuing.
Still, the researchers were deliberate in tempering enthusiasm. The findings remain confined to animal models and laboratory conditions. Clinical trials in humans are necessary before creatine could responsibly be added to any cancer treatment plan, and the scientists urged patients to consult their physicians before acting on early-stage research. The distance from laboratory discovery to clinical practice is long — and this, however genuinely promising, is only the first step.
Researchers at UCLA have discovered that creatine, the supplement familiar to gym-goers and athletes seeking stronger muscles, appears to strengthen the immune cells responsible for detecting and destroying cancer. The finding emerged from work led by professor Lili Yang and published in the journal iScience, opening a potential new avenue for making cancer treatments more effective.
The research centers on dendritic cells, which function as scouts in the immune system. These cells identify fragments of tumors and relay that information to T lymphocytes, which then mount an attack. The UCLA team found that creatine enhances how well dendritic cells perform this critical job. The mechanism is elegant: creatine acts as a kind of cellular battery, storing and releasing energy in the form of ATP when immune cells need it most. This matters because tumors create hostile environments where nutrients are scarce and competition for resources is fierce. By providing immune cells with a reliable energy source, creatine helps them stay active and functional even in these depleted conditions.
When the researchers tested the theory in animals, the results were striking. Mice receiving daily creatine doses showed significantly slower tumor growth compared to control animals. The scientists also observed more active immune cells congregating around the tumors themselves. Human cell studies produced similarly encouraging findings, with creatine boosting dendritic cell activation in laboratory conditions.
The implications for cancer treatment are substantial. Current immunotherapies—drugs designed to unleash the immune system against cancer—work for only about 20 to 40 percent of patients. By strengthening the cells that coordinate the immune attack, researchers hope to expand the pool of people who benefit from these treatments. The possibility of incorporating creatine into therapeutic cancer vaccines represents another avenue worth exploring.
Yet the scientists were careful to temper expectations. The work remains preliminary, confined to laboratory and animal models. Human clinical trials would be necessary before creatine could be recommended as part of a cancer treatment regimen. The authors emphasized that cancer patients should consult their physicians before adding any supplement to their care, even one showing promise in early research. The path from laboratory discovery to clinical practice is long, and this finding, while genuinely interesting, represents only the first step.
Citações Notáveis
Creatine acts as a cellular battery capable of storing and releasing energy when immune cells need it, allowing defenses to stay active even in nutrient-poor tumor environments— UCLA research team findings
Cancer patients should consult their doctors before consuming creatine supplements, as results remain preliminary and require validation through human clinical trials— Study authors
A Conversa do Hearth Outra perspectiva sobre a história
So creatine is just a muscle-building supplement. How does it end up helping immune cells?
It's not really about muscles in this case. Creatine works as an energy currency in cells—it stores and releases ATP, which is what cells burn for fuel. Immune cells fighting cancer operate in an energy-starved environment, so having that extra battery matters.
The mice got slower tumor growth. But is that actually meaningful, or just a lab artifact?
It's meaningful as a signal, but you're right to be skeptical. Animal models don't always translate to humans. That's why they're calling for clinical trials. The human cell work is encouraging, but it's still in a dish.
Why does this matter more than other immune-boosting discoveries?
Because immunotherapy only works for a fraction of patients right now. If creatine can make those therapies work for more people, that's a real problem solved. But it's a big if.
Should cancer patients start taking creatine now?
No. The researchers were explicit about that. This is early-stage work. Jumping to supplementation without human trials could be harmful, or just a waste of money. The science needs to mature first.
What happens next?
Clinical trials. They need to test whether creatine actually helps real cancer patients receiving real immunotherapy. That's years away, probably.